These features suggest that expression of IDH1 or IDH2 in concert with Jak2V617F impairs differentiation and probably contributes to leukemic transformation, which is consistent with correlative genetic studies showing that the primary effect of IDH1/2 mutations in MPN is that of promoting accelerated progression to post-MPN AML. The gene discussed is IDH2; the disease is myeloproliferative neoplasm.